Optimal correction of distinct CFTR folding mutants in rectal cystic fibrosis organoids

No abstract is available for this paper.

• Publication year

  2016

• Venue

  European Respiratory Journal

• Publication date

  2016-04-21

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1183/13993003.01192-2015PMID 27103391
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR

  2016cited by this paper
• Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.

  2015cited by this paper
• Rescue of NBD2 Mutants N1303K and S1235R of CFTR by Small-Molecule Correctors and Transcomplementation

  2015cited by this paper
• Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function.

  2014cited by this paper
• A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial.

  2014cited by this paper
• Measurements of Functional Responses in Human Primary Lung Cells as a Basis for Personalized Therapy for Cystic Fibrosis

  2014cited by this paper
• Correcting the Cystic Fibrosis Disease Mutant, A455E CFTR

  2014cited by this paper
• Novel opportunities for CFTR-targeting drug development using organoids

  2013cited by this paper
• Mechanism-based corrector combination restores ΔF508-CFTR folding and function

  2013cited by this paper
• A functional CFTR assay using primary cystic fibrosis intestinal organoids

  2013cited by this paper
• Ivacaftor potentiation of multiple CFTR channels with gating mutations.

  2012cited by this paper
• Isolation and in vitro expansion of human colonic stem cells

  2011cited by this paper
• Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium.

  2011cited by this paper
• Paneth cells constitute the niche for Lgr5 stem cells in intestinal crypts

  2011cited by this paper
• Structural Analog of Sildenafil Identified as a Novel Corrector of the F508del-CFTR Trafficking Defect

  2008cited by this paper
• 4'-Methyl-4,5'-bithiazole-based correctors of defective delta F508-CFTR cellular processing.

  2008cited by this paper
• The chemical chaperone CFcor-325 repairs folding defects in the transmembrane domains of CFTR-processing mutants.

  2006cited by this paper
• Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules.

  2006cited by this paper
• Dynasore, a cell-permeable inhibitor of dynamin.

  2006cited by this paper
• Discovery of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid diamides that increase CFTR mediated chloride transport.

  2005cited by this paper
• Small-molecule correctors of defective DeltaF508-CFTR cellular processing identified by high-throughput screening.

  2005cited by this paper
• Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis.

  1990cited by this paper

• Organoid-on-a-chip (OrgOC): Advancing cystic fibrosis research

  2025cites this paper
• Mitochondrial Fragmentation Induced by the CFTR Modulators Lumacaftor and Ivacaftor in Immortalized Cystic Fibrosis Cell Lines

  2025cites this paper
• Progress of personalized medicine of cystic fibrosis in the times of efficient CFTR modulators

  2025cites this paper
• Repeatability and reproducibility of the Forskolin-induced swelling (FIS) assay on intestinal organoids from people with Cystic Fibrosis.

  2024cites this paper
• Reply to: Supporting the case for a targeted approach for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with no F508del CFTR variant: further analysis for the French compassionate use programme

  2024cites this paper
• Synthesis and Evaluation of Bithiazole Derivatives As Potential α-Sarcoglycan Correctors

  2023cites this paper
• Changes in cystic fibrosis transmembrane conductance regulator protein expression prior to and during elexacaftor-tezacaftor-ivacaftor therapy

  2023cites this paper
• Cystic fibrosis airway inflammation enables elexacaftor/tezacaftor/ivacaftor-mediated rescue of N1303K CFTR mutation

  2023cites this paper
• Basic Science Perspective on Engineering and Modeling the Large Airways.

  2023cites this paper
• S945L-CFTR molecular dynamics, functional characterization and tezacaftor/ivacaftor efficacy in vivo and in vitro in matched pediatric patient-derived cell models

  2022cites this paper
• Three complex alleles of CFTR gene identified in Lebanese, Egyptian and French population and their potential impact on splicing

  2022cites this paper
• Treatment effects of Elexacaftor/Tezacaftor/Ivacaftor in people with CF carrying non-F508del mutations.

  2022cites this paper
• Organoid Technology and Its Role for Theratyping Applications in Cystic Fibrosis

  2022cites this paper
• Advances in Preclinical In Vitro Models for the Translation of Precision Medicine for Cystic Fibrosis

  2022cites this paper
• Health Characteristics of Patients with Cystic Fibrosis whose Genotype Includes a Variant of the Nucleotide Sequence c.3140-16T>A and Functional Analysis of this Variant

  2021cites this paper
• Three-Dimensional Airway Spheroids and Organoids for Cystic Fibrosis Research

  2021cites this paper
• CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine

  2020influential citation
• The preclinical discovery and development of the combination of ivacaftor + tezacaftor used to treat cystic fibrosis

  2020cites this paper
• Tissue organoid models and applications

  2020cites this paper
• Establishment of endometriotic models: the past and future

  2020cites this paper
• Characterization of the Mechanism of Action of RDR01752, a Novel Corrector of F508del-CFTR.

  2020cites this paper
• Correction of CFTR function in intestinal organoids to guide treatment of cystic fibrosis

  2020cites this paper
• Fostering the integration of basic respiratory science and translational pulmonary medicine for the future.

  2020cites this paper
• Evaluation of CFTR Channel Functions and Responses to Modulators in Patients with Cystic Fibrosis who Have a Pathogenic F508del Variant in Their Genomes

  2020cites this paper
• Lumacaftor/ivacaftor in people with cystic fibrosis with an A455E-CFTR mutation.

  2020cites this paper
• A clinical case of cystic fibrosis patient with pathogenic N1303K genotype variant with assessment of the CFTR channel function by intestinal current measurement and forskolin-induced swelling in rectal organoids

  2020cites this paper
• Cystic Fibrosis: New Insights into Therapeutic Approaches

  2020cites this paper
• Intestinal organoids to model cystic fibrosis

  2019cites this paper
• Mouse models of gastrointestinal cancers in drug development and research

  2019cites this paper
• CFTR modulator theratyping: Current status, gaps and future directions.

  2019cites this paper
• Pediatric Pulmonology

  2019cites this paper
• Take it personally: how personal we reach when we are so different from each other?

  2019cites this paper
• CFTR dysfunction in cystic fibrosis and chronic obstructive pulmonary disease

  2018cites this paper
• Assessment of p.Phe508del-CFTR functional restoration in pediatric primary cystic fibrosis airway epithelial cells

  2018cites this paper
• Personalised CFTR pharmacotherapeutic response testing and therapy of cystic fibrosis

  2018cites this paper
• Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study.

  2018cites this paper
• Physiological and pharmacological characterization of the N1303K mutant CFTR.

  2018cites this paper
• Combination potentiator ('co-potentiator') therapy for CF caused by CFTR mutants, including N1303K, that are poorly responsive to single potentiators.

  2018cites this paper
• A Proteomic Variant Approach (ProVarA) for Personalized Medicine of Inherited and Somatic Disease.

  2018cites this paper
• A novel triple combination of pharmacological chaperones improves F508del-CFTR correction

  2018cites this paper
• Physiology of the Gut: Experimental Models for Investigating Intestinal Fluid and Electrolyte Transport.

  2018cites this paper
• Self‐complementary and tyrosine‐mutant rAAV vectors enhance transduction in cystic fibrosis bronchial epithelial cells

  2018cites this paper
• Human Primary Epithelial Cell Models: Promising Tools in the Era of Cystic Fibrosis Personalized Medicine

  2018cites this paper
• Cystic fibrosis: a model for precision medicine

  2018cites this paper
• The role of stem cells in cystic fibrosis disease modeling and drug discovery

  2018cites this paper
• Repurposing therapies for the personalised treatment of cystic fibrosis

  2018cites this paper
• Diagnosis, Prognosis and Personalized Treatment of Cystic Fibrosis

  2018cites this paper
• The role of organoids in Cystic Fibrosis research

  2018cites this paper
• New treatments targeting the basic defects in cystic fibrosis.

  2017cites this paper
• Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients.

  2017cites this paper
• Tumor Organoids as a Pre-clinical Cancer Model for Drug Discovery.

  2017cites this paper
• Nasospheroids permit measurements of CFTR-dependent fluid transport.

  2017cites this paper
• Complexity of phenotypes induced by p.Asn1303Lys-CFTR correlates with difficulty to rescue and activate this protein.

  2017cites this paper
• The Contributions of Human Mini-Intestines to the Study of Intestinal Physiology and Pathophysiology.

  2017cites this paper
• CFTR functional assays in drug development

  2017cites this paper
• Toward inclusive therapy with CFTR modulators: Progress and challenges

  2017cites this paper
• CFTR Modulators: Shedding Light on Precision Medicine for Cystic Fibrosis

  2016influential citation
• Intestinal organoids and personalized medicine in cystic fibrosis: a successful patient-oriented research collaboration

  2016cites this paper
• Cystic fibrosis: a clinical view

  2016cites this paper
• Individualized medicine using intestinal responses to CFTR potentiators and correctors

  2016cites this paper